|
|
|
|
Vol. 8, Issue 10, 1877-1887, October 1997
Departments of
Physiology and
*Biochemistry and
Biophysics, University of California, San Francisco, California
94143-0444
| |
ABSTRACT |
|---|
|
|
|---|
B-type cyclins are rapidly degraded at the transition between metaphase and anaphase and their ubiquitin-mediated proteolysis is required for cells to exit mitosis. We used a novel enrichment to isolate new budding mutants that arrest the cell cycle in mitosis. Most of these mutants lie in the CDC16, CDC23, and CDC27 genes, which have already been shown to play a role in cyclin proteolysis and encode components of a 20S complex (called the cyclosome or anaphase promoting complex) that ubiquitinates mitotic cyclins. We show that mutations in CDC26 and a novel gene, DOC1, also prevent mitotic cyclin proteolysis. Mutants in either gene arrest as large budded cells with high levels of the major mitotic cyclin (Clb2) protein at 37°C and cannot degrade Clb2 in G1-arrested cells. Cdc26 associates in vivo with Doc1, Cdc16, Cdc23, and Cdc27. In addition, the majority of Doc1 cosediments at 20S with Cdc27 in a sucrose gradient, indicating that Cdc26 and Doc1 are components of the anaphase promoting complex.
| |
INTRODUCTION |
|---|
|
|
|---|
Oscillations in the activity of cyclin-dependent kinases (Cdk)
control the eukaryotic cell cycle (reviewed in Morgan, 1995
). Multicellular eukaryotes express a number of Cdks with different activities through the cell cycle. Yeasts, however, express a single
Cdk, called Cdc28 in budding yeast (Saccharomyces
cerevisiae) and Cdc2 in fission yeast (Schizosaccharomyces
pombe). The oscillation of Cdk activity in all eukaryotes depends
on phosphorylations of the kinase subunit and the cyclic expression and
degradation of cyclins, the regulatory subunits of Cdks. Entry into
mitosis requires the expression of B-type (mitotic) cyclins, and exit from mitosis requires their degradation (reviewed in Murray and Kirschner, 1989
; Nurse, 1990
). The Cdk activity associated with B-type
cyclins is required for chromosome condensation and proper formation of
the mitotic spindle. The degradation of B-type cyclins, which leads to
inactivation of the mitotic Cdk, results in chromosome decondensation,
breakdown of the mitotic spindle, and cell division.
A short N-terminal sequence found in A- and B-type cyclins, termed the
destruction box, is required for their proteolysis (Glotzer et
al., 1991
). Deletion or mutation of this sequence produces a
nondegradable cyclin, and cells or extracts expressing these
nondegradable B-type cyclins are unable to exit mitosis and remain
arrested in anaphase (Murray et al., 1989
; Holloway et
al., 1993
; Surana et al., 1993
; Sigrist et
al., 1995
). In contrast, inhibiting the machinery that is required
for cyclin proteolysis arrests cells in metaphase with unseparated
sister chromatids (Holloway et al., 1993
). This observation
suggests that additional proteins, whose destruction is required for
the separation of sister chromatids, must also be targets of the
machinery that degrades cyclins. Candidates for these regulators of
sister cohesion have recently been identified (Funabiki et
al., 1996
; Yamamoto et al., 1996
).
The degradation of cyclin is regulated by the assembly of
multiubiquitin chains onto the cyclin substrate that targets it for
proteolysis by the proteasome. In frog egg extracts, mutations in
cyclins that block their degradation also block ubiquitination (Glotzer
et al., 1991
; King et al., 1995
), and methylated
ubiquitin, an inhibitor of multiubiquitin chain formation, inhibits the
degradation of cyclins in clam egg extracts (Hershko et
al., 1991
). In yeast, a number of mutants that block cyclin
degradation also block ubiquitination (Zachariae and Nasmyth, 1996
).
Ubiquitination of proteins begins with the activation of ubiquitin by a
ubiquitin-activating enzyme (E1). The E1 forms a thiol ester with
ubiquitin and then transfers that ubiquitin onto a ubiquitin-carrier
protein (E2). Some substrates are directly ubiquitinated by an E2.
Other substrates, however, also require a ubiquitin-protein ligase
(E3), which appears to provide a higher level of specificity to the
degradation system. Finally, the 26S proteasome recognizes multiubiquitinated substrates and degrades them (reviewed in
Ciechanover, 1994
).
In budding yeast, clam, and frog, a nonspecific E1 is capable of
activating ubiquitin. A large family of E2s (UBCs) exist in
yeast, and the E2 required for Clb degradation has not yet been
definitively identified. E2-C (clam), homologues of the budding yeast
UBC4, and a novel UBC, UBCX (frog) are capable of acting as E2s for
cyclin B in reconstituted cyclin ubiquitination systems derived from
clam and frog egg extracts (King et al., 1995
; Sudakin et al., 1995
). The E3 for B-type cyclins was first
identified as a 20S complex in clam and frog egg extracts, known as the
cyclosome or anaphase-promoting complex (APC; King et al.,
1995
; Sudakin et al., 1995
). In frog egg extracts, yeast
homologues of CDC16 and CDC27 were identified as
components of this E3 complex, which appears to be active only in
mitosis in both clams and frogs.
CDC16, CDC23, and CDC27 are all
members of a family of tetratricopeptide repeat proteins and form a
complex in yeast that is required for the ubiquitination and
degradation of Clb2, the major mitotic cyclin (Lamb et al.,
1994
; Irniger et al., 1995
; Zachariae and Nasmyth, 1996
).
Temperature-sensitive mutants in any of these genes cause a metaphase
arrest with high levels of Clb2 and unseparated sister chromosomes.
Another gene, CSE1, has also been implicated in cyclin
ubiquitination (Irniger et al., 1995
). Mutations in
CDC16, CDC23, and CSE1 all result in
increased chromosome loss, suggesting that proper regulation of the
cyclin proteolysis machinery is required for faithful chromosome
segregation (Hartwell and Smith, 1985
; Xiao et al., 1993
).
We developed an enrichment for cell cycle arrest mutants in budding yeast and used this to screen for new mitotic arrest mutants. We isolated a large number of alleles of previously identified cdc (cell division cycle) mutants, and identified a novel mutant, doc1 (destruction of cyclin B). CDC26 and DOC1 are involved in the degradation of Clb2 and the products of both genes associate with the yeast APC.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Yeast Strains, Media, and Genetic Methods
All yeast strains are derivatives of W303, except those used for
complementation analysis. All strains used in this work are listed in
Table 1. Yeast media and genetic
manipulations were as described (Sherman et al., 1974
).
LH103 (mec1-1) was made by backcrossing AFS85
(MATa, mec1-1,
GAL-CLN3::URA3::cln3
, ssd1-v1::LEU2, leu2-3,112,
ura3, his3-11,15,ade2-1,
trp1-1) four times into W303 and subsequently crossing in
mad1
::HIS3 (from KH123, Hardwick and
Murray, 1995
) and bar1 (from AFS92, kindly provided by Aaron
Straight, University of California, San Francisco). BglII-cut pLH17 (CLB2-lacZ) was integrated at
CLB2, recombination and loss of the URA3 marker
were selected for on 5-fluoroorotic acid medium, and retention of
CLB2-lacZ was screened for by using
-galactosidase
(
-gal) plate assays. Strains containing GAL-CLB2 were
made by integrating pDK27 (kindly provided by Doug Kellogg, University
of California, Santa Cruz) at URA3.
|
Hydroxyurea (Sigma, St. Louis, MO) was used at 10 mg/ml, final
concentration, in medium.
-Factor (Bio-synthesis, Lewisville, TX)
was used at 1 µg/ml for bar1
strains and 10 µg/ml for BAR1 strains, from a stock solution at 10 mg/ml
in dimethyl sulfoxide (Aldrich, Milwaukee, WI). Nocodazole (Sigma) was
used at 15 µg/ml from a stock solution of 10 mg/ml in dimethyl
sulfoxide. Cycloheximide (Sigma) was used at 10 µg/ml from a stock
solution of 10 mg/ml. Nocodazole treatments were carried out at 23°C.
The other treatments were performed at various temperatures.
Plasmid Constructions
For CLB2-lacZ (pLH17), CLB2 (including the
open reading frame [ORF] and 301 bp upstream) was amplified by
polymerase chain reaction (PCR) using oligomers containing
BamHI and SalI sites at 5
and 3
ends,
respectively. This was ligated into pRS304 (Sikorski and Hieter, 1989
)
and then cut with SalI and KpnI. The KpnI site was blunted with T4 polymerase. lacZ
was cut from pAFS35 (kindly provided by Aaron Straight) by using
SalI and BamHI. The BamHI site was
blunted by using the Klenow fragment of DNA polymerase I. The
lacZ fragment was then ligated into the CLB2
construct. A second BamHI site was created 3
of
lacZ by ligation of the blunted BamHI and
KpnI sites. A 270-bp fragment of sequence immediately 3
of
the CLB2 ORF was amplified by PCR with BamHI and
SalI sites 5
and 3
, respectively. This was ligated into
pRS306 (Sikorski and Hieter, 1989
). The BamHI fragment
containing CLB2-lacZ was then ligated into the pRS306
construct containing the 3
flanking region of CLB2. The
Clb2-LacZ protein is functional and capable of acting as the sole
mitotic cyclin since pLH17 rescues the temperature sensitivity of a
strain deleted for CLB1, CLB3, and CLB4 with CLB2 replaced with a temperature sensitive allele, K3080
(Amon et al., 1993
).
pLH25 was made by PCR amplifying the ORF of DOC1 and 508 bp
upstream with a SalI site 5
and an NcoI site 3
to the ORF. The PCR product was ligated into pKH511 (kindly provided by
Kevin Hardwick, University of Edinburgh), to place a single myc tag at
the C terminus of the protein. To make pLH23, pLH25 was cut with
EcoRV and BamHI and the 1.0-kb fragment was
ligated into pDK20 (kindly provided by Doug Kellogg) cut with
SmaI and BamHI, to place the DOC1 ORF
behind the GAL1-10 promoter. pLH24 was made by cutting pLH25 with
SalI and BamHI and ligating the 1.5-kb fragment into YIplac211, cut with the same enzymes. pLH26-1B was made by cutting T1 (the original rescuing plasmid from the YCp50 library) with
NdeI and blunting with Klenow. For pLH26-1A,
URA3 was cut from pLH3 with XhoI and
XbaI and also blunted with Klenow. The URA3
fragment was ligated into the blunted NdeI site in T1.
To make pLH32, the ORF of DOC1 with 508 bp upstream was
amplified by PCR with a SalI site 5
and a KpnI
3
to the ORF. The KpnI site was designed so that the stop
codon of DOC1 was excluded and the 3
end of
DOC1 would be in-frame with a triple hemaglutinin (3×HA)
tag in YCplac111-3×HA. The DOC1 PCR product was cut with SalI, blunted with Klenow, and then cut with
KpnI. YCplac111-3×HA was cut with EcoRI,
blunted with Klenow, and then cut with KpnI. The PCR
fragment was then ligated into YCplac111-3×HA. pLH59
(DOC1-3×HA-LEU2) was made by cutting
pLH32 with SphI and SpeI and ligating the 1.8-kb
fragment into YIplac128 cut with SphI and XbaI.
All enzymes were from New England Biolabs (Beverly, MA) and used
according to the manufacturer's specifications.
Plasmids expressing Ub-R-
gal and
UbV76-V-e
K-
gal were kindly provided by
Dr. Erica Johnson (Rockefeller University, NY). Plasmids containing
HA-tagged CDC16 (pWAM10), CDC23 (pRS239), and
CDC27 (pRS248) were kindly provided by Dr. Phillip Heiter
(Johns Hopkins University, MD).
Mutant Isolation
Strain LH103 (8 × 106 cells) was mutagenized with ethyl methanesulfonate (Sigma) to 50% killing. The mutagenized cells were diluted 1:25 and allowed to recover for 12 h at room temperature in YPD. They were shifted to 37°C, to prearrest potential G1 and mitotic arrest mutants, for 2 h, then hydroxyurea was added to 10 mg/ml, and cells were incubated at 37°C for an additional 5 h. This culture was then plated on YPD plates and incubated at 23°C. Surviving colonies were replica plated onto YPD plates in duplicate with one set at 23°C and the other at 37°C to test for temperature sensitivity.
Clb2-LacZ and Visual Screen
Temperature-sensitive mutants were patched onto YPD plates and
allowed to grow overnight at 23°C. They were then replica plated to
YPD and placed at 37°C for 4 h, replica plated again to Whatman filters (VWR, San Francisco, CA) on YPD plates that contained 1 µg/ml
-factor, and returned to 37°C for 5 h. The filters were assayed for
-gal activity by freezing them in liquid nitrogen, thawing them, and incubating them on Whatman paper soaked in Z buffer
plus 5-bromo-4-chloro-3-indolyl
-D-galactoside, US
Biological, Swampscott, MA; 60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4,
0.03% 5-bromo-4-chloro-3-indolyl
-D-galactoside) at
30°C overnight.
Strains that produced bright blue patches were further analyzed by microscopy. The strains were grown in liquid medium to logarithmic phase at 23°C and then shifted to 37°C. Cells were taken and fixed in 3.7% formaldehyde (Fisher, Santa Clara, CA) after 3 and 6 h at 37°C. They were stained with 4,6-diamidino-2-phenylindole (1 µg/ml) and anti-tubulin (YOL1/34, Accurate Chemical and Scientific, Westbury, NY) diluted 1:200, and their arrest phenotype was determined by light microscopy.
Mitotic arrest mutants were tested for complementation against a
collection of known mitotic mutants. Only two mutants were not
identified as previously isolated mutants. One was cloned and named
DOC1, and the other (two alleles) has not been cloned and
appears to arrest in mitosis with pleiotropic defects. One allele of
cdc14 was also isolated; however, it was isolated as a
double mutant with a cdc16 mutant. CDC14 codes
for a phosphatase, and mutants in this gene arrest in anaphase of the
cell cycle (Wan et al., 1992
).
Cloning of DOC1
A YCp50 library (described in Hardwick and Murray, 1995
) was
transformed into doc1-1 by lithium acetate transformation
and plated on
Ura medium at 37°C. Plasmids that were capable of
rescuing the temperature sensitivity were recovered and the inserts
were sequenced at both 5
and 3
ends. These sequences were used to probe the yeast genome database.
Preparation of Antibodies against Cdc26, Western Blot Analysis, and Immunoprecipitations
The ORF of CDC26 was amplified by PCR with oligomers
containing BamHI and EcoRI sites 5
and 3
to the
ORF, respectively. This fragment was cloned into pGEX-1 cut with
BamHI and EcoRI (Smith and Johnson, 1988
),
forming a glutathione S-transferase (GST) fusion construct
(pLH29). pLH29 was transformed into Escherichia coli strain
TG1 (Maniatis et al., 1982
) and induced for expression with
0.1 mM isopropyl
-D-thiogalactoside (US Biologicals) for 2 h at 37°C. Cells were pelleted, washed with PBS (140 mM
Na2HPO4, 1.8 mM KH2PO4,
138 mM NaCl, 2.7 mM KCl, pH 7.2), pelleted again, and frozen in liquid
nitrogen. The frozen pellet was resuspended in five volumes of PBS
containing 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride,
and 200 µg/ml lysozyme and then briefly sonicated. Triton X-100 was
added to 0.5%, dithiothreitol was added to 15 mM, and cells were
sonicated again. The lysate was spun at 15,000 rpm in an SS34 rotor
(Sorvall, Burbank, CA) for 30 min, and then the supernatant was
transferred to a new tube and spun again for 20 min. The cleared
supernatant was then loaded onto a 5-ml glutathione-agarose column
(Sigma) that was then washed with PBS containing 0.5 M NaCl, 1 mM EDTA,
and 1 mM EGTA. The Cdc26-GST fusion protein was eluted with 5 mM
reduced glutathione (Sigma) in 50 mM Tris(hydroxymethyl)aminomethane, pH 8.1. The peak fractions were pooled and dialyzed into 50 mM HEPES,
pH 7.6, 50 mM KCl, and 30% glycerol. The protein was sent to Berkeley
Antibody (Berkeley, CA) where it was used to immunize a rabbit. The
rabbit serum was passed over a 50-ml column of GST protein coupled to
Affi-Gel 10 (Bio-Rad Labs, Hercules, CA) to remove anti-GST antibodies
and then affinity purified by using a 5-ml column of the Cdc26-GST
fusion protein coupled to Affi-Gel 10 (Bio-Rad).
Yeast extracts for immunoblotting and
immunoprecipitations were made by bead beating cells for two 90 s
periods, in lysis buffer A (50 mM HEPES, pH 7.6, 75 mM KCl, 1 mM
MgCl2, 1 mM EGTA, 0.1% Nonidet P-40, 50 mM NaF, 100 µM
sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, and LPC (10 µg/ml each leupeptin, pepstatin, and chymostatin; Boehringer,
Indianapolis, IN). The lysates were spun briefly to separate beads from
the lysate and then cleared by centrifugation for 5 min in an Eppendorf
microcentrifuge at 4°C. This step was repeated three times. Protein
concentrations of extracts were determined with the Bradford assay
using bovine serum albumin as a standard (Bradford, 1976
). For
immunoblotting, the extracts were adjusted to the same
protein concentration and diluted with 2× SDS sample buffer (1× SDS
sample buffer: 80 mM Tris(hydroxymethyl)aminomethane, pH 6.8, 2% SDS,
10% glycerol, 10 mM EDTA, 0.0013% bromophenol blue, 5%
2-mercaptoethanol). Standard methods were used for SDS-PAGE and protein
transfer to nitrocellulose (Harlow and Lane, 1988
). Blots were stained
with Ponceau S (Fisher) to confirm transfer and equal protein loading
and then blocked for 30 min with blotto (4% dried milk, PBS, 0.2%
Tween 20). Antibodies were used at a 1:1200 dilution for
anti-Clb2, a 1:1000 dilution for 12CA5 (BABCO, Berkeley, CA), a 1:1000
dilution for anti-
-gal (Cappel, Durham, NC), and a 1:1000 dilution
for anti-Cdc26 at either room temperature for 1 h or 4°C
overnight. Blots were washed three times 10 min in PBS with 0.2% Tween
20 (PBST) and then incubated with horseradish peroxidase-conjugated
anti-rabbit or anti-mouse antibodies (Amersham, Buckinghamshire, United
Kingdom) at a 1:5000 dilution in PBST. They were washed again and
developed by using Amersham ECL detection reagents following
manufacturer's instructions. Cdc26 protein is not detectable by
Western blot, likely due to an inability to bind to nitrocellulose.
For immunoprecipitations, antibodies were used at a 1:33 dilution for 12CA5 and a 1:50 dilution for Cdc26. Lysates with primary antibody were rotated for 1 h at 4°C, then transferred to a tube containing protein A-Sepharose beads (Pharmacia, Pleasant Hill, CA), and rotated at 4°C for an additional hour. The beads were washed twice with lysis buffer A, transferred to a new tube, washed again with PBST, and then resuspended in SDS sample buffer.
Sucrose Gradient Analysis
Solutions with lysis buffer A were prepared containing either 5% or 40% sucrose. Additional solutions with 13.75%, 22.5%, and 31.25% sucrose were made by combining various amounts of the 5% and 40% solutions. Nine hundred fifty microliters of each solution were layered into Beckman Ultra-Clear Centrifuge tubes (Beckman, Palo Alto, CA), size 0.5 × 2 inches. The gradient was incubated 12-16 h at 4°C. Yeast extract (100 µl), made as described above, was layered onto the gradient and spun at 50,000 rpm in a SW-55 rotor (Sorvall) for 4 h at 4°C. Sixteen 300-µl fractions were taken, the fractions were precipitated with 10% trichloroacetic acid, loaded onto SDS-Page gels, and analyzed by immunoblotting. Molecular weight markers were analyzed by Coomassie blue staining (Fisher).
| |
RESULTS |
|---|
|
|
|---|
Screening for New Mitotic cdc Mutants
We designed a strategy that enabled us to enrich for
temperature-sensitive budding yeast mutants that arrest in
G1 or mitosis (Figure 1). We
used mec1-1, a cell cycle checkpoint mutant, to devise
conditions under which cycling cells would die and arrested ones would
survive. mec1-1 mutants lack the checkpoint that detects unreplicated DNA and DNA damage and cannot arrest their cell cycle in
the presence of unreplicated DNA (Weinert, 1992
). As a result, treating
cycling mec1-1 cells with DNA replication inhibitors, such
as hydroxyurea, induces rapid cell death. In contrast, treating G1 or mitotically arrested mec1-1 cells with
hydroxyurea will not kill them. We exploited this difference to enrich
for mutants that caused a temperature-sensitive arrest in
G1 or mitosis. This protocol does not enrich for most
mutants arrested in S or G2 phase, because their arrest
requires the MEC1-dependent checkpoint. A mec1-1
strain was mutagenized and the mutagenized cells were shifted to 37°C
to allow potential cell division cycle mutants to prearrest and then
treated with hydroxyurea to kill the majority of cells that continued
to progress through the cell cycle. Cells that arrest in either
G1 or mitosis remain viable during the hydroxyurea treatment and form colonies on plating at the permissive temperature of
23°C.
|
We mutagenized 8 × 106 cells to 50% survival with
ethyl methanesulfonate, and 40,000 survived the mec1-1
enrichment. Of those, 1968 (5%) were temperature sensitive. To
distinguish mutants that arrested in mitosis from those that arrested
in G1, we exploited the observation that mitotic cyclins
are strongly expressed in mitosis but rapidly degraded as cells exit
mitosis and enter G1 (Amon et al., 1994
). The
temperature-sensitive mutants were tested for expression of Clb2-lacZ,
a protein fusion between the major mitotic cyclin (Clb2) and
-gal,
whose activity can be easily monitored by exposing cells to a
chromogenic substrate. Cells from mutants that expressed Clb2-lacZ
strongly at 37°C (see MATERIALS AND METHODS) were screened visually
for their arrest phenotypes. We found 32 mutants that arrested with
large budded cells at 37°C, a phenotype that is consistent with a
mitotic arrest. These mutants fell into 11 complementation groups. Each
group was tested against known mitotic mutants by complementation of
temperature sensitivity and for rescue of temperature sensitivity by
transformation with plasmids containing wild-type copies of genes known
to function in mitosis.
We isolated mitotic arrest mutations in nine genes (Table
2). One, CDC31 (one allele) is
involved in spindle pole body duplication and
cdc31ts mutants arrest in mitosis with only one
spindle pole body (Byers, 1981
; Baum et al., 1986
). Another,
PRP22 (two alleles) codes for an RNA helicase involved in
mRNA splicing (Company et al., 1991
). The alleles of
PRP22 isolated in this screen arrests in mitosis with no
microtubules (our unpublished results). TUB1 and
TUB3, the genes that code for
-tubulin, each contain an
intron. It is likely that the tubulin defect seen in these mutants is
due to a failure to splice the mRNAs from these genes that leads to a
deficiency in
-tubulin.
|
Five of the genes we identified are involved in the proteolysis of
cyclin that triggers the exit from mitosis. CDC16 (16 alleles), CDC23 (3 alleles), and CDC27 (4 alleles) encode proteins that are involved in cyclin proteolysis and
have been shown to form a multiprotein complex in yeast, frogs, and
clams (Lamb et al., 1994
; Irniger et al., 1995
;
King et al., 1995
; Sudakin et al., 1995
).
CDC20 (1 allele) has also been implicated in cyclin
proteolysis. Its homologue in Drosophila, fizzy, appears to
be required for the proteolysis of cyclin A and B (Dawson et
al., 1995
; Sigrist et al., 1995
). In yeast,
cdc20 mutants arrest in metaphase and appear to have
microtubule abnormalities (Byers and Goetsch, 1974
; Palmer et
al., 1989
; Sethi et al., 1991
). CIM3 (1 allele) is a subunit of the 26S proteasome, the multiprotein complex
that degrades ubiquitinated proteins (Ghislain et al.,
1993
).
Finally, we isolated one allele each of CDC26 and a novel
gene that we named DOC1 (destruction of cyclin B).
CDC26 is a mitotic arrest mutant, identified in the original
Hartwell screen for cdc mutants (Hartwell et al., 1970
). The
CDC26 gene is essential only at 37°C; cdc26
cells grow well at 23°C (Araki et al.., 1992
), a finding
that we confirmed in the W303 strain background.
CDC26 and DOC1 Are Required for Clb2 Proteolysis
Because the majority of mutants isolated in our screen identify
genes involved in mitotic cyclin proteolysis, we tested the cdc26 and doc1 mutants for defects in this
process. To determine whether CDC26 and DOC1 were
involved in cyclin proteolysis, we exploited the observation that
cyclin proteolysis begins in late mitosis and persists well into
G1 (Amon et al., 1994
). Haploid yeast cells can
be arrested in G1 by treatment with mating pheromone. Thus
in MATa cells arrested in G1 by
-factor
treatment, the B-type cyclin proteolysis machinery is active and
ectopic expression of the CLB2 gene does not lead to Clb2
protein accumulation. In a cdc16-1 mutant, however, Clb2
protein does accumulate in G1-arrested cells as a result of
a defect in the ubiquitination of Clb2 (Irniger et al.,
1995
; Zachariae and Nasmyth, 1996
).
To determine the half-life of mitotic cyclins, we integrated a copy of
CLB2 under the control of the inducible GAL promoter into
wild-type and mutant strains. Wild-type and the doc1-1 and cdc26-100 mutants isolated in our screen were arrested with
-factor and shifted to 37°C for 20 min, and CLB2
expression was induced with galactose. Cycloheximide and glucose were
added after a 30-min induction to stop Clb2 protein synthesis and
CLB2 transcription. Clb2 protein levels were monitored by
Western blotting using anti-Clb2 antibodies. Figure
2A shows that the half-life of Clb2 in
wild-type cells is less than 1 min. In doc1-1 and
cdc26-100 mutants, the half-life of Clb2 protein increases
to greater than 20 min. This defect is rescued in doc1-1
and cdc26-100 by the integration of a wild-type copy of the
corresponding gene at the LEU2 locus (our unpublished
results). Others have also identified CDC26 as playing a
role in cyclin proteolysis (Zachariae et al., 1996
).
|
The Clb2 destruction defect in cdc26-100 and
doc1-1 appears to be specific to Clb2 and not a general
defect in the proteolysis of ubiquitinated substrates. Figure 2B
shows that cdc26-100 and doc1-1 cells have no
defect in the degradation of two substrates that require ubiquitination
for destruction: Ub-R-
gal, which generates
-gal with an
N-terminal arginine, a substrate that is degraded by the N-end rule
(Figure 2B, Ub-R-
gal; Bachmair et al., 1986
), and
UbV76-V-e
K-
gal, a fusion with a
noncleavable N-terminal ubiquitin (Figure 2B, UBV76-
gal;
Johnson et al., 1992
). Cycloheximide was added to cells expressing Ub-R-
gal or UbV76-V-e
K-
gal
to inhibit protein synthesis, and stability of the substrates was
determined by Western blotting with anti-
-gal antibodies at
different times after inhibiting protein synthesis. cim3-1, a mutant in a subunit of the 26S proteasome (Ghislain et
al., 1993
) that degrades all ubiquitinated proteins, is defective
in the degradation of both substrates (Figure 2B, lanes 1-8).
To see if the mutant phenotype of cdc26-100 and doc1-1 cells reflected defects in mitotic proteolysis, we overexpressed a mitotic cyclin in these mutants. cdc26-100 and doc1-1 strains containing an integrated copy of GAL-CLB2 are unable to grow on galactose at their permissive temperature (data not shown). We suggest that these strains are already crippled in their Clb2 destruction machinery at the permissive temperature and that excess Clb2 overloads this machinery and results in a cell cycle arrest.
Cloning and Disruption of DOC1
Like previously identified mitotic cyclin proteolysis mutants, doc1-1 mutants arrest as large budded cells at 37°C with a single nucleus and a short spindle (Figure 3A and Table 3).
|
|
DOC1 was cloned by complementing the temperature sensitivity of
doc1-1 with a genomic yeast library on a centromeric vector (Figure 3B, plasmid T1). The minimal complementing region contains a
single ORF coding for a protein of 283 amino acids. A construct containing the ORF of DOC1 and 508 bp upstream, with a
single myc tag on the C terminus and no sequences 3
to the ORF,
complements the temperature sensitivity and Clb2 proteolysis defect of
the doc1-1 mutant (Figure 3B, plasmid pLH24). In addition,
a construct containing a frameshift at an NdeI site 297 bp
into the DOC1 ORF, will not rescue the temperature
sensitivity of doc1-1 (Figure 3B, plasmid pLH26-1B).
Disruption of DOC1 by insertion of the URA3 gene
at the NdeI site (Figure 3B, plasmid pLH26-1A) results in
viable cells that grow poorly at 23°C, forming colonies in which most
of the cells have large buds and cannot grow at 37°C. Coincidentally,
DOC1 lies directly upstream of the CSE1 gene, which is also implicated in cyclin proteolysis (Xiao et al.,
1993
; Irniger et al., 1995
). These genes have distinct
functions in proteolysis because plasmids that contain only the
CSE1 gene do not complement doc1-1. The Doc1
amino acid sequence is shown in Figure 3C. The Doc1 sequence lacks
obvious motifs and shows no homology to proteins of known function;
however, it does show homology to rat (Lee et al., 1995
) and
mouse expressed sequence tag sequences (GenBank accession numbers
H33761 and W49295, respectively). The doc1-1 mutation was
recovered and sequenced. The mutation changes a conserved serine
(Ser-137) to phenylalanine.
Cdc26 and Doc1 Associate with APC Components (Cdc16, Cdc23, and Cdc27)
Cdc16, Cdc23, and Cdc27 form a complex in yeast (Lamb et
al., 1994
) and their homologues are components of a 20S complex in frog egg extracts (King et al., 1995
). This complex behaves
as a ubiquitin ligase for B-type cyclins, and CDC16,
CDC23, and CDC27 are required for the
ubiquitination of Clb2 in yeast (Zachariae and Nasmyth, 1996
). We
therefore tested whether Cdc26 or Doc1 associated with Cdc16, Cdc23, or
Cdc27. Extracts were made from exponentially growing wild-type or
cdc26
strains that had been transformed with centromeric
plasmids containing HA-tagged versions of CDC16,
CDC23, CDC27, and DOC1. Cdc26 was
immunoprecipitated with polyclonal antibodies against Cdc26. The bound
proteins were probed by Western blotting with mouse monoclonal
antibodies against HA (12CA5) to test whether the tagged proteins
coimmunoprecipitate with Cdc26.
Figure 4 shows that immunoprecipitation
of Cdc26 in a wild-type strain results in the coimmunoprecipitation of
HA-tagged Cdc16, Cdc23, Cdc27, and Doc1. No HA-tagged Cdc16, Cdc23,
Cdc27, or Doc1 was detected when immunoprecipitations were performed on
extracts made from a cdc26
strain. These experiments
suggest that Cdc26 is a functional component of the APC, and this
suggestion is strengthened by the observation that the
Xenopus homologue of Cdc26 is a component of the purified
APC (M. Kirschner, personal communication).
|
The association of Doc1 with Cdc26 could be interpreted in two ways.
Either Doc1 is a component of the APC or there are two pools of Cdc26,
one associated with the APC and one bound to Doc1. To distinguish these
possibilities, we analyzed the sedimentation of Doc1 and Cdc27 in a
sucrose gradient. Extracts from exponentially growing cells expressing
both HA-tagged Doc1 and HA-tagged Cdc27 were separated on a 5-40%
sucrose gradient (Figure 5). The majority of Doc1 sediments in a peak at approximately 20S, coinciding with the
sedimentation of Cdc27. The sedimentation coefficient of the frog and
clam APC is 20S (King et al.., 1995
; Sudakin et
al., 1995
).
|
Genetic Interactions among CDC26, DOC1, and Other Mitotic Mutants
Genetic interactions between mutants often indicate that they
function in the same pathway. We found that double mutants of cdc26-100 and doc1-1 are synthetically lethal
(Table 4), suggesting that the functions
of Cdc26 and Doc1 overlap. In addition, cdc26-100 is
synthetically lethal with cdc16-1 and cdc23-1,
and cdc26-100 cdc27-1 double mutants have a lower
permissive temperature than either single mutant. doc1-1
double mutants with cdc16-1 or cdc23-1 have a
lower permissive temperature than any of the single mutants. The
interactions of cdc26-100 and doc1-1 with
mutants involved in the ubiquitination of mitotic cyclins do not simply
reflect synthetic interactions between any pair of mitotic mutants.
Double mutants between cdc26-100 or doc1-1 and
cim5-1 (a subunit of the 26S proteasome, required for the
destruction of ubiquitinated proteins; Ghislain et al.,
1993
) have the same nonpermissive temperature as the
cdc26-100 or doc1-1 single mutants.
|
| |
DISCUSSION |
|---|
|
|
|---|
We have identified two new components of the cyclin proteolysis
machinery, Cdc26 and Doc1, and show that Cdc26 and Doc1 are physically
associated with the APC/cyclosome, the multiprotein complex that acts
as an E3 for cyclin ubiquitination (King et al., 1995
;
Sudakin et al., 1995
; Zachariae and Nasmyth, 1996
). Similar
results were recently obtained for CDC26 by Zachariae et al. (1996)
.
We isolated temperature-sensitive mitotic mutants by using an
enrichment that kills the majority of cells passing through S phase at
the nonpermissive temperature. Of the 32 temperature-sensitive mitotic
arrest mutations we isolated, 27 are in genes involved in the cyclin
proteolysis machinery; 1 is in CDC31, a gene required for
spindle pole body duplication; and 2 are in PRP22, which
encodes a splicing function that is probably required to ensure
adequate levels of
-tubulin synthesis. Why do proteolysis mutants
dominate the metaphase arrest mutants isolated in both this screen and the original Hartwell screen for cdc mutants? We believe
that three factors account for this observation. First, although
defects in the mitotic spindle can arrest cells in mitosis by
transiently activating the spindle assembly checkpoint, the checkpoint
eventually adapts to persistent defects thus allowing cells to exit
mitosis (Hardwick, Rudner, Wiess, Winey, and Murray, unpublished
results). Because cells that adapt and leave mitosis with a defective
spindle are likely to suffer lethal errors in chromosome segregation, mutants that cause spindle defects may have died during the prolonged incubation at 37°C that was used during the mutant enrichment. Second, there appears to be considerable functional overlap among the
components that assemble the mitotic spindle, so that mutations that
inactivate single components do not cause a mitotic arrest. For
example, strains lacking the Kar3 microtubule motor are viable, although mitosis in these cells is clearly abnormal (Meluh and Rose,
1990
). Finally, the integrity of some spindle functions, such as the
protein kinase Mps1 (Hardwick et al., 1996
), are required for the spindle assembly checkpoint to detect defects in the spindle. As a result, lesions in these components would not arrest cells in
mitosis.
cdc26 and doc1 mutants arrest in metaphase and
cannot destroy mitotic cyclins that are expressed in
G1-arrested cells. Unlike mutations in the proteasome,
cdc26 and doc1 mutants do not suffer general
defects in ubiquitin-mediated proteolysis. A substrate that is
recognized by a destabilizing N-terminal amino acid or a noncleavable
N-terminal ubiquitin is degraded normally in cdc26 and
doc1 mutants. Thus, these observations suggest that the
mitotic arrest of cdc26 and doc1 reflects their
inability to degrade mitotic cyclins and proteins, such as Cut2 and
Pds1, whose destruction is required for sister chromatid separation
(Funabiki et al., 1996
; Yamamoto et al., 1996
).
This conclusion is supported by both genetic and biochemical evidence
for interactions of Cdc26 and Doc1 with the APC. Immunoprecipitates
prepared with anti-Cdc26 antibodies contain Cdc16, Cdc23, and Cdc27,
all of which are characterized components of the APC, as well as Doc1.
In addition, a population of Doc1 cosediments with Cdc27. This evidence
suggests that both Cdc26 and Doc1 are associated with the APC. Because
we cannot easily measure the amounts of Cdc26 and Doc1 relative to
other components of the APC, it is unclear whether Cdc26 and Doc1 are stoichiometric components of the APC. The observation that neither Cdc26 or Doc1 show any homology to cloned subunits of the biochemically purified Xenopus APC suggests that Cdc26 and Doc1 cannot be
tightly associated with all APC complexes (King et al.,
1995
). The observation that doc1-1 is synthetically lethal
with cdc26-100, but not with mutants in other components of
the APC, suggests that Doc1 and Cdc26 may play partially overlapping
roles in cyclin proteolysis. Although cdc26
mutants grow
well at 23°C, they are synthetically lethal with cdc16-1
and cdc23-1, suggesting that Cdc26 may play a role in
stabilizing the APC and that this role is dispensable under optimal
conditions but becomes essential under environmental stress or in the
presence of defects in other APC components.
Defects in the mitotic spindle activate a spindle assembly
checkpoint that arrests eukaryotic cells in mitosis (Hoyt et
al., 1991
; Li and Murray, 1991
). Activation of the checkpoint
prevents the destruction of mitotic cyclins and sister chromatid
separation, suggesting that the principal action of the checkpoint is
to inhibit the proteolysis of mitotic cyclins and proteins that play a
role in maintaining the linkage between sisters. It is currently
unclear whether this inhibition is due to inactivation of the APC
itself or to reactions that protect specific substrates from a normally active APC in checkpoint-arrested cells. Further biochemical comparison between APC components in anaphase- and checkpoint-arrested extracts should help to resolve this issue.
| |
ACKNOWLEDGMENTS |
|---|
We thank Phil Hieter, Lee Hartwell, Mark Winey, Carl Mann, Erica Johnson, Kevin Hardwick, Doug Kellogg, and Aaron Straight for yeast strains and plasmids; Cathy Mistrot for technical assistance; the members of the Murray and Morgan labs for invaluable discussions and critical reading of the manuscript, especially Sue Biggins, Rey-Huei Chen, Hironori Funabiki, Marion Shonn, Dana Smith, and Alex Szidon. L.H.H. is supported by a National Science Foundation Fellowship. This work was supported by grants to A.W.M. from the National Institutes of Health, the March of Dimes, and the David and Lucile Packard Foundation.
| |
FOOTNOTES |
|---|
Corresponding author: Department of
Physiology, Box 0444, University of California, 513 Parnassus Avenue,
San Francisco, CA 94143-0444.
| |
REFERENCES |
|---|
|
|
|---|
-transducin homolog, is required for a subset of microtubule-dependent cellular processes.
Mol. Cell. Biol.
11, 5592-5602This article has been cited by other articles:
![]() |
D. S. Andersen and N. Tapon Drosophila MFAP1 Is Required for Pre-mRNA Processing and G2/M Progression J. Biol. Chem., November 7, 2008; 283(45): 31256 - 31267. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Wise and D. D. Pravtcheva Oligosyndactylism Mice Have an Inversion of Chromosome 8 Genetics, December 1, 2004; 168(4): 2099 - 2112. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Dahan and M. Kupiec The Saccharomyces cerevisiae gene CDC40/PRP17 controls cell cycle progression through splicing of the ANC1 gene Nucleic Acids Res., May 7, 2004; 32(8): 2529 - 2540. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Arai, J. S. Kasper, J. R. Skaar, S. H. Ali, C. Takahashi, and J. A. DeCaprio Targeted disruption of p185/Cul7 gene results in abnormal vascular morphogenesis PNAS, August 19, 2003; 100(17): 9855 - 9860. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Hall, M. P. Torres, G. K. Schroeder, and C. H. Borchers Mnd2 and Swm1 Are Core Subunits of the Saccharomyces cerevisiae Anaphase-promoting Complex J. Biol. Chem., May 2, 2003; 278(19): 16698 - 16705. [Abstract] [Full Text] [PDF] |
||||
![]() |
|